Matthew Rathbun
Primary Care · Evergreen Park, ILNPI 1184239667
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations.
Across 152 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$614
- Novo Nordisk$580
- AstraZeneca$355
- Mannkind Corporation$208
- Amgen$141
- Corcept Therapeutics$96
- plus $1K from 33 others
What the payments were for
- Food & beverage$3,160100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 25 | $614 |
| Novo Nordisk | 21 | $580 |
| AstraZeneca | 24 | $355 |
| Mannkind Corporation | 11 | $208 |
| Amgen(2 entities) | 8 | $141 |
| Corcept Therapeutics | 4 | $96 |
| Novartis | 5 | $94 |
| Lundbeck LLC | 4 | $88 |
| Bayer | 3 | $87 |
| IBSA Pharma Inc. | 5 | $82 |
| Ultragenyx Pharmaceutical Inc. | 3 | $65 |
| Pfizer | 3 | $64 |
| Amarin Pharma, Inc. | 3 | $53 |
| Dexcom, Inc. | 2 | $53 |
| Edwards Lifesciences | 2 | $48 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| Exact Sciences | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Boehringer Ingelheim | 2 | $29 |
| Boston Scientific | 1 | $29 |
| Cequr Corporation | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Halozyme Inc | 1 | $23 |
| Amphastar Pharmaceuticals, Inc. | 1 | $21 |
| Intuity Medical Inc | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $20 |
| AbbVie | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Corium, LLC | 1 | $19 |
| Mylan Specialty L.p. | 1 | $17 |
| Amryt Pharma Holdings Ltd | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Clarus Therapeutics Inc. | 1 | $14 |
| Roche Diabetes Care, Inc. | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Theracosbio, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,172 in reported general payments places this provider in the 85th percentile of 150 primary care providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 181 | $126,148 |
| OzempicSemaglutide | 57 | $77,008 |
| JardianceEmpagliflozin | 77 | $64,695 |
| XareltoRivaroxaban | 76 | $49,362 |
| TrulicityDulaglutide | 45 | $49,089 |
| MounjaroTirzepatide | 31 | $48,514 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $47,119 |
| FarxigaDapagliflozin Propanediol | 33 | $41,019 |
| JanuviaSitagliptin Phosphate | 76 | $32,955 |
| TradjentaLinagliptin | 23 | $22,070 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $13,238 |
| RybelsusSemaglutide | 11 | $11,910 |
| MyrbetriqMirabegron | 18 | $11,208 |
| Atorvastatin Calcium | 770 | $8,872 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $7,101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $64 | $126,148181 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $614 | $97,60276 claims |
| Novo NordiskOzempic, Rybelsus | $580 | $88,91768 claims |
| Boehringer IngelheimJardiance, Tradjenta | $29 | $86,766100 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $355 | $54,20258 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $11,20818 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $2,064216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 150 primary care providers in Illinois.
Other primary care in Evergreen Park
- Nicole LorangElk Grove Village$19K
- Allison LindstromChicago$15K
- Rachel ProkopfOak Park$13K
- Dawn ConwayChicago$11K
- Anne MaynardGlen Ellyn$9K
- Megan McLuckieHoffman Estates$9K
- Megan NiemiecNew Lenox$7K
- Ashley CarterChicago$7K
- Blake WoodsMetropolis$6K
- Jennifer VazquezChicago$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.